Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. - Cantu,M.G.; Buda,A.; Parma,G. (J Clin Oncol, 2002)